Yes, I agree. The Senate votes this week on the Cures Act. It should pass. If so, faster FDA approval of drugs to treat these rare diseases for young patient populations is expected. If AVXL 2-73 obtains any approval for any disease, the FDA will be able to rely on data in the clinical trial obtaining approval to approve use of the same drug for other diseases as well (Cures Act specifies that). In any event, a physician may write a prescription for off label use (Alzheimer's for example) of any drug that the FDA has approved for any use.